Fangliang Zhang (Imaginechina via AP Images)

The big mon­ey: Poised to make drug R&D his­to­ry, a Chi­na biotech un­veils uni­corn rac­ing am­bi­tions in a bid to raise $350M-plus on Nas­daq

Al­most ex­act­ly three years af­ter Shang­hai-based Leg­end came out of nowhere to steal the show at AS­CO with jaw-drop­ping da­ta on their BC­MA-tar­get­ed CAR-T for mul­ti­ple myelo­ma, the lit­tle play­er with Big Phar­ma con­nec­tions is tak­ing a gi­ant step to­ward mak­ing it big on Wall Street. And this time they want to seal the deal on a glob­al rep af­ter stak­ing out a uni­corn val­u­a­tion in what’s turned out to be a bull mar­ket for biotech IPOs — in the mid­dle of a pan­dem­ic.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.